93 results about "Anticoagulant Agent" patented technology

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

The present invention embodies: methods; compounds, their pharmaceutically acceptable analogs, isomer, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof that have particular biological properties; devices; diagnostic and other assays; and the uses of such methods, compounds, devices and assays. Common throughout these embodiments is specific selective reduction of intravascular thromboplastin antecedent activity, which results in a safe antithrombotic effect. A particularly prominent application or the invention relates to diagnosis and treatment of patients which have, or are at risk of, developing thrombosis, thrombotic injury, or vaso-occlusive diseases, such as myocardial infarction, stroke, restenosis after angioplasty, thrombotic diseases, etc. Another particularly prominent feature of the present invention is its high level of hemostatic safety at optimal efficacy. Also, the present invention is compatible for use in combination with other traditional therapeutic agent such as another antithrombotic, antiplatelet, thrombolytic, or anticoagulant agents.

Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.

The invention provides a cell preservation solution and application thereof. The cell preservation solution is prepared from the following components in parts by weight: 60 to 1000 parts of pH buffer, 10 to 150 parts of osmotic pressure maintenance agent, 4 to 55 parts of anticoagulant, 1 to 30 parts of mucolytic agent, 800 to 5000 parts of fixing agent, 1 to 150 parts of component A, 10 to 30 parts of component B and 10000 to 20000 parts of water, wherein the component A is prepared from sodium azide and lauryl sodium sulfate according to a weight ratio of (1 to 10) to (2 to 110); the component B is carbon disulfide. The cell preservation solution of the invention has a better impurity treatment effect, and reduces the interference factors in cell samples; at the same time, target cells therein can retain the characteristics of structural morphology for a long time, thereby facilitating the medical detection and analysis of the target cells, and the cost is low.

The invention refers to a heparin compound and its preparation method and application. The heparin compound is a heparin zinc-potassium double salt demonstrated by the formula of R(ZnOH)aKb. The R represents the heparin radical and a is between 3 and 5, b between 1 and 3. The heparin compound can be made through the following preparation method: dissolve the sodium heparin into the water and contact with the cinnamene cation exchange resin to get the heparin solution; add an amount of zinc hydroxide and potassium hydroxide to the heparin solution, whisk and dry it and get the mentioned solid heparin compound. The heparin compound can be used as the anticoagulant agent as well as the main material of the anti thrombus medicine. The heparin zinc-potassium as the anticoagulant agent meets not only the requirements of not affecting the components' balance and stability of the blood samples to be tested but also the requirement of the solubility in the blood. When it is chosen as the main resource of the anti thrombus medicine, the heparin zinc-potassium releases slowly, has long effect of medicine and no toxicity and is good for the zinc-adding of the human body.

The invention provides a blood virus RAN protective agent and a blood sampling tube. The blood virus RAN protective agent is prepared by dissolving the following components in DEPC (diethyl pyrocarbonate) solution 100-500mg/ml glycine, 1-5mg/ml aprotinin, 1-5mg/ml wortmannin, 10-40mg/ml glutathione, 100-500mg/ml sodium thiocyanate, 1-3mg/ml anticoagulant and 5-20mg/ml membrane protective agent. The blood virus RAN protective agent provided by the invention is capable of supplying long-term protection to virus RNA in blood under room temperature, preventing degradation and pollution of virus RNA and effectively guaranteeing accuracy and validity of blood sample.

An object of the present invention is to provide an activated blood coagulation factor X (FXa) inhibitor that reduces the risk of bleeding caused by the treatment of thromboembolism. The present invention provides an oral anticoagulant agent comprising a compound represented by the following formula (1):

or a pharmacologically acceptable salt thereof, or a hydrate thereof, as an active ingredient, wherein (A) a factor involved in the risk of bleeding caused by the anticoagulant agent is selected as a dose determinant; (B) a reference value of the dose determinant is set; (C) the dose determinant of a patient in need of administration is measured; and (D) the dose of the anticoagulant agent is selected with the reference value as an index.

The invention discloses a blood anticoagulant which consists of the following raw materials in parts by weight: 2.5-3 parts of sodium citrate, 0.3-0.4 part of citric acid, 2.2-2.6 parts of glucose, 0.2-0.25 part of sodium dihydrogen phosphate, 1-1.5 parts of ethylenediamine tetraacetic acid disodium salt and 100 parts of water, wherein the raw materials are sequentially added into 100 parts of water, dissolved and uniformly stirred at normal temperature, and 14ml of the blood anticoagulant is dissolved in 100ml of pig blood. The anticoagulation effect of the blood anticoagulant disclosed by the invention is not less than 3 days, and then the phenomenon of blood hemolysis is solved. By adopting the blood anticoagulant, the fibrinogen aggregation phenomenon of the blood is solved.

The invention relates to a manufacturing method of a coaxial electrostatic spinning magnetic anastomosed artificial blood vessel. The method comprises the following steps: 1) preparing a coaxial electrostatic spinning solution; and preparing two solutions: namely a heparin sodium solution and a poly L-lactide-caprolactone solution, wherein the heparin sodium solution is a core layer solution for coaxial electrostatic spinning, and the PLCL solution is a shell layer solution for coaxial electrostatic spinning; 2) carrying out 3D printing of an electrostatic spinning receiver: 2.1) carrying outCT angiography examination on a patient before an operation; 2.2) measuring the blood vessel length L and the blood vessel diameter D, which need to be replaced; 2.3) drawing a 3D model of an electrostatic spinning receiver by using SolidWorks software; and 2.4) manufacturing an electrostatic spinning receiver by using a 3D printer; and 3) manufacturing a coaxial electrostatic spinning magnetic anastomosed artificial blood vessel. The prepared magnetic anastomosed artificial blood vessel has a good microstructure, hydrophilicity and stable heparin slow release performance, and the blood compatibility, mechanical properties and animal in-vivo implantation experiments show that the magnetic anastomosed artificial blood vessel has the advantages that the anastomosis process is convenient andrapid, an anastomosed stoma is not narrow, and anticoagulant application is avoided.

The invention relates to a vein remaining needle which mainly comprises a remaining rubber tube, a puncture needle guide disc, a sealing tube plug and a puncture needle, wherein the vein remaining needle is provided with at least one hirudin injection device capable of preventing blood from forming thrombi in the vein remaining needle; the liquid injection outlet at the bottom of the hirudin injection device can be selectively communicated with the inner cavity of the vein remaining needle; and the inner cavity of the hirudin injection device is filled with a hirudin biological anticoagulant, and the top is provided with a driving device capable of driving the hirudin biological anticoagulant in the inner cavity to be injected into the inner cavity of the vein remaining needle. Because the vein remaining needle adopts the hirudin as an anticoagulant and fully utilizes the super strong and super long anticoagulation properties of the hirudin biological anticoagulant, the vein remaining needle fully guarantees that the blood flowing back into the vein remaining needle because of a negative pressure can not generate thrombi, thereby ensuring the smoothness of each channel of the vein remaining needle, avoiding the adverse impact resulted from puncturing again and utilizing heparin sodium which should be used immediately after being prepared, and effectively reducing the pain of patients and the labor strength of medical personnel. Besides, the invention has the advantages of easy manufacturing process and simple implementation, and is beneficial to popularization.

The invention provides a valve material with synergistic anticoagulation and anti-calcification functions and a preparation method of the valve material. The preparation method comprises the followingsteps: carrying out glutaraldehyde crosslinking treatment on an animal-derived biological valve material; immersing the treated valve material in confining liquid containing an amino compound to perform treatment for 0.5-6 h, and then confining aldehyde groups remaining after glutaraldehyde crosslinking; then putting the valve material into a reaction solution containing an anticoagulant and a cross-linking agent, and carrying out cross-linking treatment for 6-24 hours at 4-37 DEG C; and finally, cleaning the valve material to obtain the valve material, and storing the valve material in a glutaraldehyde or isopropanol/glycerol mixed solvent. The method can effectively solve the problems of easy calcification and thrombus formation caused by aldehyde group residue in the valve material prepared by an existing method, and the valve material prepared by the method disclosed by the invention can be used as a valve material required by aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

The invention discloses an anticoagulant and metal-organic framework compound dual-modified in-vitro blood circulation pipeline coating and a preparation method thereof. The anticoagulant of the coating is selected from heparin, hirudin, citric acid or argatroban, and the metal-organic framework compound in the coating is MOF-Ag or MOF-Cu; the coating is obtained by fixing the metal-organic framework compound on the inner wall of an in-vitro blood circulation pipeline through dopamine and then fixing the anticoagulant on a dopamine layer with the metal-organic framework compound in a chemical grafting mode. The coating is high in stability, can improve blood compatibility and has excellent anticoagulation and antibacterial effects; and the in-vitro blood circulation pipeline with the coating can be applied to conventional hemodialysis, blood adsorption and continuous blood purification treatment.

The invention relates to a peripheral blood mobilizing concentrated cell therapeutic agent for treating premature ovarian failure. The method for preparing peripheral blood, such as mobilized peripheral blood concentrated cells, comprises the following steps: providing peripheral blood, such as mobilized peripheral blood concentrated cells, of a biological sample, and placing the peripheral blood in a sterile bag containing an anticoagulant for later use; a protective cap on an input tube of the automatic cell separation system is taken down, an injector is connected to a Luer locking connector of the input tube and passes through a thrombus filter at a slow and stable speed, an anticoagulant biological sample is transferred into a disposable sterile separation cup, and the mixed sample is shaken along a horizontal shaft; the automatic cell separation system is a closed PXP separation system and consists of four parts, namely a disposable sterile separation cup, a control module, a separation base and a software processing system, and putting the disposable separation cup into a control module, and centrifuging in a programmable centrifugal machine to obtain mobilized peripheral blood concentrated cells. The method disclosed by the invention has excellent effects as described in the specification.

The invention relates to substituted polycyclic aryl and heteroaryl pyrimidinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The invention provides an accurate, economical, automatable, high throughput method for the determination of the concentration of glycosaminoglycan anticoagulants, including low molecular weight heparin (LMWH) anticoagulants, in aqueous solutions. A method for cleaning a unit of manufacturing equipment used in the preparation of a LMWH to obtain an acceptable residual concentration of LMWH is further provided.

The invention relates to the technical field of biological preserving fluid, in particular to cell preserving fluid for in-vitro analysis and detection and a preparation method thereof. The cell preserving fluid is prepared from the following components in a concentration range: 60 to 75 v/v percent of a cell fixing agent, 0.6 to 0.9 g/100 mL of an osmotic pressure regulator, 0.2 to 0.5 g/100 mL of an anticoagulant, 0.3 to 0.6 g/100 mL of chitosan quaternary ammonium salt and 0.05 to 0.2 g/100 mL of trehalose; and the solvent is ultra-pure water, and the pH value is 7.0-7.6. A small amount of trehalose and chitosan quaternary ammonium salt are combined, so that the protective effect can be effectively enhanced, autolysis decay of cells is effectively reduced, and the integrity of cell preservation is improved. When the cell preserving fluid is prepared, ultra-pure water is used for dissolving components except the cell curing agent, the dissolving effect of the components can be effectively improved, the uniform and stable cell preserving fluid is obtained, and batch production of the cell preserving fluid is facilitated.

The invention relates to the technical field of hydraulic oil, in particular to a high-temperature-resistant precipitation antagonist for hydraulic oil. The precipitation antagonist is prepared from the following components in percentage by weight: 70 to 80 percent of base oil, 2 to 6 percent of 6-butylated hydroxytoluene, 2 to 5 percent of zinc dialkyl dithiophosphate, 2 to 10 percent of anticoagulant, 1 to 3 percent of dispersing agent, 1 to 3 percent of accelerant, 1 to 3 percent of PH regulator, 2 to 5 percent of stabilizer, 3 to 8 percent of water retention agent, 2 to 5 percent of defoaming agent and 1 to 2 percent of clarifying agent. The main shaft drives the pushing mechanism to rotate, so that the roller rolls along the disc, and the roller is in intermittent rolling fit with the curved surface block. When the rollers roll along the curved surface blocks, the rollers roll to drive the limiting rods to move downwards, and the limiting rods push the walking plates to slide downwards along the sliding grooves; and meanwhile, the walking plate extrudes the shaking spring, and the walking plate is pushed to slide upwards under the elastic action of the shaking spring; the operations are repeated so as to make the walking plate to shake vertically, so that the intermediate product C is filtered and purified, and the precipitate antagonist is prepared.

The invention discloses a preparation method of high-absorbability resin for sanitary towels, belonging to the technical field of fine chemical engineering. The preparation method comprises the following steps: (1) neutralizing acrylic acid to a certain extent, and polymerizing the neutralized acrylic acid, a crosslinking agent, an initiator, a foam stabilizer and a blood anticoagulant under ventilation conditions to form a colloid; (2) adding fine powder during granulation of the polymerized colloid, and conducting drying, crushing and screening to control the particle size distribution of particles; and (3) adding assistants such as a blood anticoagulant and a blood affinity agent during surface treatment of the semi-finished product to obtain a finished product SAP. The high-absorbability resin prepared by the preparation method in the invention has the characteristics of good blood absorption performance and high absorption speed.

A complex of glucosamine having a purity of at least about 99 wt. % and a maximum halide content of about 0.01 wt. %, and a therapeutic drug having a pK_a of less than 7. Preferably, the complex is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers, povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant coated complex will be stable upon exposure to ambient temperature and/or the atmosphere. Suitable therapeutic drugs fall into the following classes: α- and β-Adrenergic Agonists; Narcotic and Non-Narcotic Analgesics; Anorexics; Antiallergics; Antianginals; Antiarrhythmics; Antiasthmatics; Antibiotics; Anticoagulants; Anticonvulsants; Antidepressants; Antidiabetics; Antihistaminics; Antihypertensives; Nonsteroidal Anti-Inflammatories; Antimigraines; Antineoplastics; Antiparkinsonians; Antipsychotics; Antipyretics; Antispasmodics; Antithrombotics; Antiulceratives; Anxiolytics; Decongestants; Diuretics; Hepatoprotectants; Sedatives; and Vasodilators.